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Abstract 
Molecular profiling of urothelial cancers for therapeutic and prognostic potential has been 
very limited due to the absence of cancer-specific targeted therapies. We describe here 2 
clinical cases with a histological diagnosis of an invasive sarcomatoid and a poorly differenti-
ated carcinoma favoring urothelial with some neuroendocrine differentiation, two of the rarer 
types of urothelial cancers, which were evaluated for mutations in 212 genes for single-
nucleotide variants and copy-number variants and 53 genes for fusions associated with solid 
tumors. In both cases, we identified variants in 2 genes, ARID1A and CDKN2A, indicative of 
the role of dysregulation of chromatin remodeling and cell cycle control as being common 
features of bladder cancer, consistent with the proposed model of tumorigenesis in these 
rare, highly aggressive pathological subtypes. The presence of a KRAS mutation in the poorly 
differentiated cancer and a TP53 mutation in the sarcomatoid tumor is indicative of a distinc-
tive profile and adds a potential layer of molecular stratification to these rarer histological 
subtypes. We present a comparative analysis of the histological, clinical, and molecular pro-
file of both cases and discuss the potential to delineate these tumors at the molecular level 
keeping in mind the possible therapeutic implications. © 2018 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
Bladder cancer is the most common malignancy involving the urinary system and the 
ninth most common malignancy worldwide [1], responsible for ~150,000 deaths per year 
worldwide and about 5% of all new cancers in the US [2]. Invasive urothelial carcinoma in-
volving the urinary bladder is very well known for divergent differentiation [3], with transi-
tional cell carcinoma being the most common histological type accounting for 90% of cases. 
Sarcomatoid carcinomas of the bladder are rare (0.6% of bladder cancers – SEER Statistics) 
with only about 24 cases reported so far [4]. Similarly, neuroendocrine tumors of the blad-
der are equally rare (<0.5% of all bladder cancer malignancies) with ~12 cases being re-
ported [5]. Prognosis with both variant morphologies is poor with an aggressive clinical 
course and rapid onset of metastatic disease. Given the rarity of the 2 variant morphotypes 
presented in the current analysis, it is difficult to draw any conclusions about the optimal 
treatment strategy or prognostic markers due to the small number of reported cases. 
Here we present 2 cases (initial pathology, genomic findings, and clinical follow-up) of 
the rare pathological subtypes of urothelial cancer, a sarcomatoid tumor and a poorly differ-
entiated urothelial carcinoma (PDUC) with some neuroendocrine differentiation. To our 
knowledge, this is the first report of these rare variant morphologies of urothelial carcino-
mas being described with clinical genomic profiling to identify potential targeted therapeutic 
approaches. 
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Case Reports 
PDUC with Some Neuroendocrine Differentiation 
A 70-year-old man with a diagnosis of invasive PDUC of the right lateral wall of the 
bladder was initially noted by his primary care provider to have persistent microscopic he-
maturia. However, cystoscopy conducted 2 months later did not identify any tumors. CT 
scans of the abdomen and pelvis with contrast were negative for metastatic disease. Three 
months later, he developed macroscopic hematuria and anemia and a new 3–4 cm broad-
based nodular lesion was identified in the right lateral wall of the bladder on repeat cystos-
copy. Transurethral resection of these lesions and several clots in the bladder were noted 
during that procedure and were removed, resulting in resolution of his gross hematuria. 
Pathology of these lesions noted a high-grade, muscle-invasive PDUC with some neuroendo-
crine differentiation of the right lateral wall of the bladder (Fig. 1a, b). He was clinically 
staged as stage II, cT2 cN0 cM0. A PET/CT scan done at the same time showed no evidence of 
regional or distant metastatic disease.  
Invasive Sarcomatoid Urothelial Carcinoma  
A 69-year-old man with a family history of pancreatic cancer in his mother and a broth-
er initially underwent an evaluation for hematuria followed by a partial cystectomy when a 
cystoscopy identified a bladder diverticulum. Histological examination identified a high-
grade bladder tumor with sarcomatoid features (Fig. 1c, d). Associated lymph nodes were 
negative for malignancy. The tumor had been resected with negative margins and no further 
treatment was advised at that time. After 9 months of surveillance, a repeat cystoscopy re-
vealed the possibility of recurrent disease and restaging MRI scan of the abdomen per-
formed at the same time revealed the presence of bulky pelvic and retroperitoneal adenopa-
thy. A transurethral resection of a recurrent tumor in the trigone area showed invasive sar-
comatoid urothelial carcinoma, which locally progressed as confirmed on CT scans 1 month 
later. Chemotherapy with gemcitabine and cisplatin was initiated, but after a brief period of 
clinical improvement, a repeat staging CT scan after about 2.5 months of treatment revealed 
progression of his pelvic and retroperitoneal disease. Given a high PD-L1 score of 95%, 
treatment with atezolizumab was initiated but the patient progressed clinically after 2 cycles 
of treatment and then expired. 
Genomic Analyses and Clinical Interpretation 
Ultrasound-guided core-needle biopsies were histologically evaluated for diagnosis of 
malignancy (Fig. 2) and formalin-fixed paraffin-embedded (FFPE) samples were shipped to 
The Jackson Laboratory for Genomic Medicine (JAX) CLIA lab by the ordering physicians 
(W.F. and C.A.T.) to be processed using a clinically validated (CLIA/CAP) assay called the 
ActionSeq PlusTM. The assay included a DNA-based panel comprising 212 cancer-related 
genes for which all coding exons are sequenced (to allow for detection of somatic single-
nucleotide variants, indels, and copy-number variants) and a RNA-based panel for 53 genes 
known to form fusions. Data were analyzed to identify variants of actionability, i.e., those 
with therapeutic, prognostic, or diagnostic relevance. 
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Two genes were mutated in both cases; actionable variants were identified in ARID1A 
(p.Q1172* – PDUC and p. H782Tfs*51 – sarcomatoid) and CDKN2A (p. N42Kfs*77 – PDUC 
and p. W110* – sarcomatoid). Additionally, we identified an actionable KRAS (p.G12D) vari-
ant in the PDUC and 2 actionable variants in the tumor suppressors TP53 (p. R273C) and 
FBXW7 (p. R465C) in the sarcomatoid cancer. While no variants of uncertain significance 
were identified in the PDUC, we did identify 1 variant of uncertain significance in NFE2L2 
(p.E82V) in the sarcomatoid tumor (Table 1). No actionable copy-number variants or fusions 
were identified in either case. A comprehensive summary of the potential therapies, variant 
classification, FDA-approved therapies and potential clinical trials identified for the patient-
specific mutational profile is listed in Table 2. While there were no FDA-approved targeted 
therapies identified for urothelial tumors in any of the relevant drug classes, FDA-approved 
drugs for these mutations in other cancers (metastatic or locally advanced solid tumors) 
were listed in the genomic testing report as potential options for off-label use, consistent 
with the AMP/ASCO guidelines for reporting of somatic variants [6].  
Treatment Outcomes 
PDUC with Some Neuroendocrine Differentiation 
The patient was initially started on neoadjuvant chemotherapy with cisplatin-etoposide 
(i.v. cisplatin 80 mg/m2 on day 1, i.v. etoposide 80 mg/m2 on days 1, 2, and 3). This was 
planned for 4 cycles. During the completion of this first cycle, a revision of his pathology 
stated that the neuroendocrine component of his tumor was minimal, with scant evidence of 
neuroendocrine cells and very weak stain synaptophysin, thus favoring the diagnosis of 
PDUC. After a multidisciplinary discussion, the patient’s neoadjuvant chemotherapy regimen 
was changed to dose-dense methotrexate-vinblastin-doxorubicin-cisplatin (ddMVAC) (i.v. 
cisplatin 70 mg/m2, i.v. methotrexate 30 mg/m2, i.v. vinblastin 3 mg/m2, I.V. doxorubicin 30 
mg/m2 on day 1 every 2 weeks), a category 1 NCCN guideline recommendation.  
The patient completed 3 cycles of neoadjuvant ddMVAC without serious complications 
except for moderate cytopenia, fatigue, poor appetite, and nausea. Two weeks after comple-
tion of that regimen, restaging CT scans of the abdomen, pelvis, and chest showed no radio-
logical evidence of disease. The plan is now to perform a radical cystectomy, to be followed 
likely by active monitoring for development of metastatic disease. There remains a signifi-
cant risk for metastatic disease recurrence and having the next-generation sequencing test 
results may help identify future treatment options or clinical trials if the patient develops 
metastatic disease. 
Sarcomatoid Urothelial Carcinoma 
The patient passed away in the interim during genomic testing and was unable to bene-
fit from the results of genomic testing. 
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Discussion 
Precision medicine aims to identify novel targets for treating rare and difficult-to-treat 
cancers. To advance the field and identify novel treatment options for patients, broad molec-
ular profiling is needed. Here we describe the molecular profiling results of 2 cases with 
urothelial cancers that identified potential treatment options for the patients. We identified 
some interesting profiles which offer the opportunity to identify new treatment options and 
may support novel molecular disease classifications in the future.  
Mutations in 2 genes, ARID1A and CDKN2A, were identified in both our cases and they 
have been shown to occur in 25 and 5% of urothelial carcinomas, respectively, indicative of 
the role of dysregulation of chromatin remodeling and cell cycle control in these rare, highly 
aggressive pathological subtypes. Evaluation of 347 cases across a broad complement of 
cancers demonstrated that CDKN2A was more likely to be independently associated with 
ARID1A in a multivariate analysis (OR D 3.98, 95% CI: 1.36–11.8, p D 0.01, p = 0.01).  
In addition, we identified a mutation in KRAS in 1 of the 2 cases (PDUC). Mutations in the 
RAS oncogenes (HRAS, KRAS, and NRAS) are found in ~11–13% of bladder tumors and occur 
in all stages and grades, with mutations in KRAS being the least frequent [7]. Profiling of 
urothelial cancers across multiple studies have not identified co-occurrence of KRAS with 
CDKN2A mutations [8], however, a single study has reported the co-occurrence of a KRAS 
substitution with an ARID1A truncation mutation in a stage IV high-grade urothelial carci-
noma in a 51-year-old male [9] indicative of the rarity of this genomic profile. The co-
occurrence of the ARID1A and KRAS mutation in the PDUC could therefore possibly account 
for the aggressive and poorly differentiated nature of the tumor. In contrast to the PDUC, the 
sarcomatoid urothelial carcinoma had actionable mutations in 3 other genes (TP53, FBXW7, 
and NFE2L2) known to harbor aberration in bladder cancer. TP53 is the most commonly 
mutated gene in bladder cancer observed at a frequency of ~15% in non-muscle-invasive 
tumors as is the sarcomatoid tumor. Mutations in TP53 have been shown to co-occur with 
either ARID1A or CDKN2A [9] with aberration in the CDK pathway genes being the second 
most common mutation across most cancers next to TP53 [10]. Mutations in FBXW7 are 
observed in 10% of bladder cancers across all stages [7] and mutations in NFE2L2 are ob-
served in ~8–11% of bladder tumors [11], particularly the basal subtype [12], based on 
samples in TCGA suggesting a potential role for the oxidative stress pathway in progression 
of bladder cancer. While co-occurrence of FBXW7 mutations with TP53 has been reported in 
a single case report, of a high-grade, advanced-stage tumor from a 71-year-old woman, from 
the lymph node metastasis specimen which had a micropapillary architecture [9], mutations 
in NFE2L2 have not been shown to co-occur with TP53 mutations [12] across a comprehen-
sive study evaluating ~400 bladder cancers, contributing to the novelty of this genomic pro-
file and providing further insight into the possible genomic changes involved in the devel-
opment and evolution of sarcomatoid urothelial carcinoma. 
There are currently no molecularly targeted agents approved for the treatment of blad-
der cancer despite a significant amount of effort in recent times to profile bladder tumors. By 
following the AMP/CAP/ASCO guidelines on reporting actionability of cancer-specific genes, 
we were able to identify potential drug classes for clinical consideration (Table 2). These 
included FDA-approved drugs (for a different indication) as well as some experimental ther-
apies. In addition, we were able to identify a number of clinical trials for each one of the pa-
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tients based on their genomic profile, although all of the trials were recruiting patients 
broadly across solid tumors. Most noteworthy is a trial listed for the ARID1A and KRAS muta-
tions (NCT02576444) which is a phase II study of the PARP inhibitor olaparib (AZD2281) 
alone and in combination with AZD1775, AZD5363, or AZD2014 in advanced solid tumors 
across different molecular profiles including any mutation in ARID1A, as well as protocol-
defined mutations in KRAS and TP53. The TP53 mutation identified in the sarcomatoid case 
did not fit inclusion criteria, but the mutations in ARID1A and KRAS were eligible, resulting in 
the inclusion of this trial in the genomic testing report. All in all, molecular profiling has 
identified a number of genomic-marker-driven treatment approaches for patients with 
urothelial cancers, but these treatments should be accessed through clinical trial enrollment 
rather than off-label use of drugs.  
Though the ARID1A and CDKN2A genes identified in our cases are amongst those known 
to be commonly associated with urothelial carcinoma, to our knowledge this study is the 
first clinical case report comparing and identifying unique genomic profiles in 2 rare patho-
logical subtypes of urothelial cancer. The identification of the co-occurring combinations of 
ARID1A/KRAS in the PDUC and the TP53/FBXW7 in the sarcomatoid subtype adds a layer of 
potential stratification across these two histological subtypes. Further, our documentation of 
these rare co-occurrences in high-grade urothelial carcinomas adds an additional case re-
port to the existing literature of single cases currently reported for each combination, ampli-
fying the potential of broad-based targeted clinical trials. In addition, given the rarity of 
these tumors, with only 24 clinical cases of sarcomatoid tumors [4] and ~12 cases of urothe-
lial carcinoma with neuroendocrine component [5] being reported, our evaluation also adds 
to the knowledgebase of these rare urothelial carcinoma morphologies, both from a genomic 
profile perspective as well as identification of potential targeted therapies and trials since 
there are currently no targeted FDA-approved therapies specific for urothelial cancer.  
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Fig. 1. a, b Pathology sections of a poorly differentiated urothelial carcinoma: ×4 (a), ×40 (b). c, d Pathology 
sections of a sarcomatoid carcinoma: ×20 (c), ×40 (d). 
 
 
 
Fig. 2. Immunostained sections of the tumors: synaptophysin (poorly differentiated urothelial carcinoma) 
(a), GATA3 (sarcomatoid) (b), and CAM5.2 (sarcomatoid) (c). 
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Table 1. Variants reported in both cases 
         
         
Histology Gene Protein  
change 
cDNA Transcript Coordinate Variant  
type 
Predicted  
effect 
         
         
Case 1        
PDUC with areas  
of neuroendocrine  
differentiation 
ARID1A p.Q1172* c.3514C>T NM_006015.4 chr1:26772607 Transition Missense 
CDKN2A p.N42Kfs77* c.126_127delTA NM_000077.4 chr9:21974700 Deletion FS/truncation 
KRAS p.G12D c.35G>A NM_033360.3 chr12:25245350 Transition Missense 
                  Case 2        
Sarcomatoid  
urothelial  
carcinoma 
ARID1A p.H782Tfs*51 c.2343delA NM_006015.4 chr1:26762242 Deletion FS/truncation 
CDKN2A p.W110* c.330G>A NM_000077.4 chr9:21971029 Transition Nonsense 
FBXW7 p.R465C c.1393C>T NM_033632.3 chr4:152328233 Transition Missense 
TP53 p.R273C c.817C>T NM_000546.5 chr17:7673803 Transition Missense 
        
        
PDUC, poorly differentiated urothelial carcinoma; FS, frameshift mutation. 
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Table 2. Clinically significant variants with potential therapies and clinical trials listed in genomic testing 
reports 
        
        
Histology Gene Classification Drug classes FDA approved  
for tumor type 
FDA approved for  
other indications 
Potential  
clinical trials 
        
        
Case 1       
PDUC with areas  
of neuroendocrine  
differentiation 
ARID1A 
c.3514C>T 
Tier II √ PARP inhibitor None Olaparib1 
Niraparib2 
Rucaparib2 
NCT02576444 
 O AKT inhibitor N/A N/A NCT02576444 
CDKN2A 
c.126_127delTA 
Tier II √ CDK4/6 inhibitor None Palbociclib1 
Ribociclib2 
Abemaciclib2 
NCT02693535, 
NCT02334527 
 O Multikinase inhibitor N/A N/A NCT02478320, 
NCT02540876 
KRAS 
c.35G>A 
Tier II √ MEK inhibitor None Cobimetinib  
Trametinib 
NCT01827384, 
NCT02022982 
NCT03108131, 
NCT02079740 
NCT03162627 
 O ERK inhibitor N/A N/A NCT02857270, 
NCT03051035 
 O KRAS ASO inhibitor N/A N/A NCT03101839 
                Case 2       
Sarcomatoid  
urothelial  
carcinoma 
ARID1A 
c.2343delA 
Tier II √ PARP inhibitor None Olaparib1 
Niraparib2 
Rucaparib2 
NCT02576444 
 O AKT inhibitor N/A N/A NCT02576444 
CDKN2A 
c.330G>A 
Tier II √ CDK4/6 inhibitor None Palbociclib1 
Ribociclib2 
Abemaciclib2 
NCT02693535, 
NCT02334527 
 O Multikinase inhibitor N/A N/A NCT02478320, 
NCT02540876 
FBXW7 
c.1393C>T 
Tier II O CHK1 inhibitor N/A N/A NCT02873975 
TP53 
c.817C>T 
Tier II O P53 gene therapy N/A N/A NCT02842125 
 O P53 vaccine N/A N/A NCT02432963 
 O WEE1 inhibitor N/A N/A NCT02576444 
        
        
PDUC, poorly differentiated urothelial carcinoma; √, approved therapies; O, experimental therapies; Tier I, strong clinical significance; Tier II, potential clinical 
significance; Tier III, unknown clinical significance. 
1 Currently being investigated in a clinical trial. 2 Additional “in-class” drug not currently under active investigation in a clinical trial. 
        
        
 
